

What is claimed is:

1. A method of treating or inhibiting hepatic fibrosis in a mammal in need thereof, which comprises providing to said mammal an effective amount of a CCI-779.
2. The method according to claim 1, wherein CCI-779 is provided to said mammal by oral or intravenous infusion.
3. The method according to claim 1, wherein CCI-779 provided to said mammal by administration of a prodrug, derivative, pharmaceutical salt or analog of CCI-779 that forms an effective amount of CCI-779 in the body.
4. The method according to claim 1, wherein CCI-779 is administered by direct targeting to the liver.
5. The method according to claim 1, wherein CCI-779 is provided to said mammal by oral dose.
6. A method of treating or inhibiting hepatic cirrhosis in a mammal in need thereof, which comprises providing to said mammal an effective amount of a CCI-779.
7. The method according to claim 6, wherein CCI-779 is provided to said mammal by oral or intravenous infusion.
8. The method according to claim 6, wherein CCI-779 provided to said mammal by administration of a prodrug, derivative, pharmaceutical salt or analog of CCI-779 that forms an effective amount of CCI-779 in the body.
9. The method according to claim 6, wherein CCI-779 is administered by direct targeting to the liver.

10. The method according to claim 1, wherein CCI-779 is provided to said mammal by oral dose.